Lifecore Biomedical
LFCR
93 hedge funds and large institutions have $340M invested in Lifecore Biomedical in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 38 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
0% more funds holding
Funds holding: 93 → 93 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.63% less ownership
Funds ownership: 92.18% → 90.54% (-1.6%)
18% less capital inflows, than outflows
Capital inflows: $14.9M | Capital outflows: $18.1M
29% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.95M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.83M |
| 3 |
Foundry Partners
Minneapolis,
Minnesota
|
+$1.2M |
| 4 |
Morgan Stanley
New York
|
+$1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ariel Investments
Chicago,
Illinois
|
-$5.07M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$2.81M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.42M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.33M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$986K |
LFCR Hedge Fund Activity: Q4 2016 in Review
93 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2016, worth a combined $340M — up 1.1% from $337M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LFCR positions and 9 closed out — a net gain of 2 holders — while 27 added to existing stakes and 38 trimmed.
The largest buyer was Fuller & Thaler Asset Management, adding an estimated $2.95M. The largest seller was Ariel Investments, cutting an estimated $5.07M.
- 93 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $340M of Lifecore Biomedical stock for Q4 2016, up 1.1% quarter-over-quarter.
- 11 funds opened new Lifecore Biomedical positions in Q4 2016 and 9 closed out, a net change of +2 holders.
- The largest Lifecore Biomedical buyer in Q4 2016 was Fuller & Thaler Asset Management, an estimated $2.95M added.
- The largest Lifecore Biomedical seller in Q4 2016 was Ariel Investments, an estimated $5.07M sold.
Based on aggregated 13F filings for Q4 2016.